Clinical trial data from the STEP 1 trial published in the New England Journal of Medicine shows that constipation occurs in approximately 24% of people taking semaglutide 2.4 mg for weight management
Slower titration may buy tolerability at the cost of time
Dizziness: Rare, but reported occasionally, especially if injecting without eating for extended periods afterward
Clinical studies have demonstrated significant efficacy in supporting weight management and metabolic health when combined with lifestyle modifications
General guidance includes: Inject 7.5 mg once weekly Administer under the skin of the abdomen, thigh, or upper arm May be used with or without meals Rotate injection sites regularly Never change your dose without medical advice
If youre considering medication for weight loss, the first and most important step you can take is to connect with a provider for a medical consultation to discuss these risks in detail